Francesco De Rubertis
| Francesco De Rubertis | |
|---|---|
| Born |
January 23, 1970 Italy |
| Alma mater |
University of Pavia (B.A.) University of Geneva (Ph.D.) |
| Occupation | Partner at medicxi |
| Spouse(s) | Sandra Henchoz De Rubertis |
Francesco De Rubertis (born January 23, 1970) is a partner at medicxi, a venture capital firm with offices in London, Jersey and Geneva, having co-founded the firm in February 2016.[1] Prior to that he was a partner at another venture capital firm, Index Ventures, having led the firm’s efforts to establish its life sciences practice after joining in 1997.[2]
Early life and education
De Rubertis was born in Italy. He graduated from the University of Pavia with a Bachelor of Arts in Genetics and Microbiology, before earning a Ph.D. in Molecular Biology from the University of Geneva, where he also met his wife, Sandra Henchoz, who was a fellow student. De Rubertis engaged in postdoctoral research in molecular genetics at the Whitehead Institute at Massachusetts Institute of Technology (MIT), and later earned the Chartered Financial Analyst (CFA) designation.[3]
Career
After his postdoctoral work at MIT, in 1997 De Rubertis moved back to Geneva, where he joined Index Ventures and helped co-found the firm’s life sciences practice. In 2009 he moved to London (site of another Index office) where he continues to reside.[4]
De Rubertis is responsible for all of Index Ventures’ investments in the life sciences. He has served on the Boards of Directors of many companies, including Addex Therapeutics (SIX: ADXN), CellZome (acquired by GlaxoSmithKline for $120 Million [5]), Genmab (Nasdaq Copenhagen: GEN), Molecular Partners (SIX: MOLN), PanGenetics (acquired by Abbott Laboratories), and Parallele Bioscience (acquired by Affymetrix).[6]
In 2012 De Rubertis spearheaded the launch of Index Ventures’ $200 Million life sciences fund in partnership with GlaxoSmithKline (GSK) and Johnson & Johnson (J&J), to invest in early-stage biotechnology companies .[7]
De Rubertis is the author of several publications in international scientific journals.[8]
In 2010 De Rubertis was named by BioWorld as one of 28 "movers and shakers" predicted to shape the biotechnology industry over the next two decades .[9]
In October 2012 De Rubertis was named by Xconomy as one of 40 of “Young and Proven” biotech venture capitalists.[10]
De Rubertis is a member of the Strategic Advisory Board of the University of Geneva.[11]
External links
References
- ↑ "J&J and GSK join Medicxi's European life sciences push". FT. February 2, 2016.
- ↑ "Veni, vidi, V.C." (PDF). University of Geneva student magazine. November 6, 2009.
- ↑ "Executive Profile". Bloomberg Businessweek. May 10, 2013.
- ↑ "Veni, vidi, V.C." (PDF). University of Geneva student magazine. November 6, 2009.
- ↑ "GSK acquires Cellzome 100%". EuroBiotechnologyNews. May 15, 2012.
- ↑ "GSK Press release". GlaxoSmithKline. May 15, 2012.
- ↑ "Index Launches Its First Life Sciences Fund: $200M And Partnering With Glaxo and Johnson & Johnson". TechCrunch. March 20, 2012.
- ↑ "Google Scholar search: "Francesco De Rubertis"".
- ↑ "The Future Is Here: Who Will Shape Biotech Over the Next 20 Years? BioWorld Says…" (PDF). BioWorld 20th Anniversary Edition. 2010.
- ↑ "Who Will Survive the Biotech VC Downturn? The Young and the Proven". Xconomy. October 22, 2012.
- ↑ "Index Ventures Partner bio: Francesco De Rubertis".